Tag: Sentinel

Boston Scientific closes acquisition of Claret Medical

Boston Scientific has announced that it has recently closed its acquisition of Claret Medical, which developed and commercialised the Sentinel cerebral embolic protection system—the...

Boston Scientific to buy cerebral protection system company

Boston Scientific has signed an agreement to acquire Claret Medical, which developed and commercialised the Sentinel cerebral embolic protection system. The device is used...

ADVERTORIAL: Sentinel Cerebral Protection System provides reassurance to both physicians and...

Compared with first-generation devices, new-generation transcatheter aortic valve implantation (TAVI) devices—along with iterative approaches in technique and imaging—have partially reduced the documented stroke rates...

ADVERTORIAL: “All patients” should receive cerebral protection when undergoing TAVI procedures

Data indicate that patients who undergo TAVI with the Sentinel Cerebral Protection System (Claret Medical) have a significantly higher rate of stroke-free survival than...

Fifty US centres are now using Claret Medical’s Sentinel cerebral protection...

Since it received FDA clearance in June 2017, the Sentinel cerebral protection system (Claret Medical) has become an emerging standard of care in the...

Claret Medical closes on series C financing of US$14.5m

Claret Medical has announced that it has closed on a series C financing of US$14.5m led by Lightstone Ventures, with participation from existing investors...

All-comers data indicate stroke-free survival is improved with Sentinel embolic protection...

Jochen Wöhrle (Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Germany) and his team report in JACC: Cardiovascular Interventions that, in an...

US centres of TAVI excellence start to use newly approved Sentinel...

Claret Medical has announced that several of the largest centres of excellence for transcatheter aortic valve implantation (TAVI) have now performed the first US...

Sentinel becomes first cerebral protection device to receive FDA approval

Claret Medical has received regulatory clearance from the FDA for its Sentinel cerebral protection system, via de novo classification, meaning that the device can...

FDA advisory panel recommend de novo approval of Sentinel cerebral protection...

In an open public hearing of the FDA’s circulatory system devices panel, according to a press release, nearly all panel members recommended the de...

Meta-analysis indicates embolic protection does reduce stroke after TAVI

In a research letter published in the Journal of the American College of Cardiology, Gennaro Giustino (The Icahn School of Medicine, Mount Sinai Hospital,...

TCT 2016: SENTINEL trial fails to meet overall primary efficacy endpoint...

The SENTINEL trial, which was presented at the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October-2 November, Washington , DC, USA) today, has not...

Claret Medical submits application for FDA approval of its cerebral protection...

Claret Medical has announced its filing of a marketing application with the FDA for clearance of the Sentinel cerebral protection system. According to a...

TCT 2016: Pivotal trial on cerebral protection device to be presented...

Data from the SENTINEL pivotal IDE trial will be presented during a late-breaking trial session at the  2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29...

TCT 2016: Late-breakers and first report investigations announced

The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 first report investigations that will be presented at the 2016 Transcatheter...